

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box. 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/003,136	11/15/2001	Sharon T. Wong-Madden	NEB-20C2CD3	6015	
28986 7	1590 12/02/2003		EXAMINER		
NEW ENGL	AND BIOLABS, INC	FRONDA, CH	IRISTIAN L		
32 TOZER ROAD					
BEVERLY, MA 01915			ART UNIT	PAPER NUMBER	
			1652		

DATE MAILED: 12/02/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/003,136	WONG-MADDEN ET AL.					
Office Action Summary	Examiner	Art Unit					
·							
The MAILING DATE of this communication app	Christian L Fronda	1652 orrespondence address					
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1) Responsive to communication(s) filed on	<u>.</u> .						
2a)⊠ This action is FINAL . 2b)□ This a	action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) ☐ Claim(s) <u>7 and 9-11</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>7 and 9-11</u> is/are rejected.	6)⊠ Claim(s) <u>7 and 9-11</u> is/are rejected.						
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or	8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers							
9)☐ The specification is objected to by the Examiner.							
10)⊠ The drawing(s) filed on <u>15 November 2001</u> is/ar	10)⊠ The drawing(s) filed on <u>15 November 2001</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) \square The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. §§ 119 and 120							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No.							
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s)					
 Notice of Neterences Cited (*10-032) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 11. 	5) Notice of Informal Pa						

Art Unit: 1652

DETAILED ACTION

1. Claims 7, 9, 10, and 11 are under consideration in this Office Action.

Claim Rejections - 35 U.S.C. § 112, 1st Paragraph

- 2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

 The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 3. Claims 7, 9, 10, and 11 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicants' arguments filed 9/5/2003 have been fully considered but they are not persuasive. The Examiner respectfully disagrees with Applicants' position that the specification provides a written description of glycosidases from *Xanthomonas manihotis*, *Xanthomonas holcicola*, and *Xanthomonas oryzae* for the reasons of record and the reasons stated below.

The claims are directed to any method for modifying any carbohydrate using any glycosidase derived from any *Xanthomonas* strain wherein the glycosidase is an exoglycosidase selected from the group consisting of a fucosidase, a mannosidase, a xylosidase, a glucosidase, a galactosidase, N-acetylglucosaminidase, and a hexosaminidase. The term "derived" expands the scope of the claims to encompass any fucosidase, mannosidase, xylosidase, glucosidase, galactosidase, N-acetylglucosaminidase, or hexosaminidase which is expected to have any structure/amino acid sequence that differs from the recited enzymes contained in *Xanthomonas* strains. The specification, however, only provides a written description for a fucosidase, mannosidase, xylosidase, glucosidase, galactosidase, and N-acetylglucosaminidase from *Xanthomonas*. The specification does not provide a written description for any method for modifying any carbohydrate using any glycosidase derived from any *Xanthomonas* strain wherein the glycosidase is an exoglycosidase selected from the group consisting of a fucosidase, a mannosidase, a xylosidase, a glucosidase, a galactosidase, and N-acetylglucosaminidase.

Applicants have failed to sufficiently describe the claimed invention, in such full, clear, concise, and exact terms that a skilled artisan would recognize Applicants were in possession of the claimed invention.

Art Unit: 1652

Amending the claims to recite that the fucosidase, mannosidase, xylosidase, glucosidase, galactosidase, and N-acetylglucosaminidase are obtained from *Xanthomonas* may overcome this rejection.

Claim Rejections - 35 U.S.C. § 112, 2nd Paragraph

- 4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 5. Claims 9-11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 9 the phrase "biological properties which differ from the carbohydrate prior to modification" renders the claim vague and indefinite because the meaning of the phrase is not known and it is not known what specific biological properties of the modified carbohydrate are to be different from the "carbohydrate prior to modification". Claims 10 and 11 which depend from claim 9 are also rejected because they do not correct the defect of claim 9.

In claim 10, the phrase "immunogenic properties" renders the claim vague and indefinite because the specific immunogenic properties which are to differ from the carbohydrate prior to modification are not known and not recited in the claim.

Conclusion

- 6. No claim is allowed.
- 7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL.** See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR

Application/Control Number: 10/003,136

Art Unit: 1652

1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L. Fronda whose telephone number is (703)305-1252. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703)308-3804. The fax phone number for this Group is (703)308-0294. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703)308-0196.

CLF

PONNATIVAPUACHUZAMURTHY SUPERVISORY PATERT FXAMINER TECHNOLOGY CANTON 1000 Page 4